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The Women’s Health Initiative (WHI) randomized trial observed an increase in both breast cancer 
incidence and mortality among users of estrogen plus progestin (E+P). (E+P is a type of hormone 
replacement therapy (HRT), used to alleviate postmenopausal symptoms.) In contrast, most 
observational studies had previously reported that the use of E+P was associated with an increased 
incidence of breast cancer, but decreased mortality. Some researchers have posited that E+P use is 
associated with breast cancers with a more favorable prognosis. It has also been suggested that 
differences between studies in rates of mammography, and/or the amount of time between 
menopause and initiation of E+P therapy, could explain the disparate findings. 
Dr. Rowan Chlebowski (Harbor-UCLA Medical Center), Drs. Polly Newcomb and Ross Prentice 
(Public Health Sciences, FHCRC), and their collaborators addressed these questions using data 
from the WHI observational study. They assessed the relationship between E+P and breast cancer 
incidence, as well as mortality, comparing women who had used E+P with women who had no 
history of HRT. For the sake of comparability they selected a study sample which was similar to 
participants in the original randomized controlled trial. In both studies, women had to be 
postmenopausal, between the ages of 50-79 years at study entry, have at least a 3-year anticipated 
survival, have no record of prior hysterectomy or breast cancer, and have had a mammogram less 
than 2 years before study entry which was not suspicious for breast cancer. 41,449 women were 
included in this study, including 25,328 HRT non-users and 16,121 E+P users. 
The investigators found that women using E+P were younger, more likely to be white, alcohol 
drinkers, and have a body mass index of less than 25 kg/m2 compared to HRT non-users. E+P 
users had been using E+P for an average of 5 years. During follow-up (mean: 11.3 years), 2,236 
invasive breast cancers were diagnosed. E+P users had higher rates of breast cancer than non-
users (0.6% vs 0.4% per year, respectively, HR 1.55, 95% CI 1.41-1.70). The sooner women had 
initiated use of E+P after menopause, the higher their risk of breast cancer. Among women 
diagnosed with breast cancer, survival from the time of diagnosis was similar in women who used 
E+P compared to non-users (HR = 1.03, 95% CI 0.79-1.35). The use of E+P was associated with a  
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higher risk of death due to breast cancer (HR 1.32, 95% CI 0.90-1.93), and a higher risk of death 
from all causes (HR 1.65, 95% CI 1.29-2.12), compared to HRT non-use. 
In this study, Chlebowski et al. were able to address some important questions about differences 
between findings of the WHI randomized trial vs. observational studies regarding the relationship 
between use of E+P and breast cancer mortality. The WHI randomized trial had observed an 
increased risk of death, but prior observational studies generally observed a decreased risk of dying 
of breast cancer associated with E+P use, leading to the hypothesis that E+P might cause breast 
cancers with a favorable prognosis. By creating an observational study with a similar population to 
the randomized trial in terms of eligibility requirements, the authors were able to demonstrate that 
certain differences between studies may indeed be responsible for the disparate findings in earlier 
studies. Specifically, there were differences in mammogram history between the observational 
studies and the randomized trials; women were required to have a recent negative mammogram to 
enter the clinical trial, and both arms of the trial (E+P vs non-users) received regular mammograms 
during study follow-up according to protocol. However, in observational studies, women using E+P 
tended to receive mammograms much more regularly than HRT non-users. Regular screening leads 
to the diagnosis of more early-stage, favorable tumors. Thus, differences in screening practices may 
have confounded the observational studies and created an apparent association between E+P use 
and better breast cancer survival. 
These results, combined with the original randomized trial (also cited below), provide evidence that 
E+P increases risk of breast cancer incidence and mortality among postmenopausal women. In 
particular, initiation of E+P soon after menopause is more strongly associated with breast cancer 
incidence and mortality than delayed E+P inititation. 
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Modified from Chlebowski et al. 
Breast cancer mortality by estrogen plus progestin (E+P) 
use at baseline. 
 
